- Home
- NTHI vs JYNT Comparison
NTHI vs JYNT Comparison
Compare NTHI & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTHI
- JYNT
- Stock Information
- Founded
- NTHI 2008
- JYNT 2010
- Country
- NTHI United States
- JYNT United States
- Employees
- NTHI N/A
- JYNT N/A
- Industry
- NTHI Biotechnology: Pharmaceutical Preparations
- JYNT Multi-Sector Companies
- Sector
- NTHI Health Care
- JYNT Miscellaneous
- Exchange
- NTHI Nasdaq
- JYNT Nasdaq
- Market Cap
- NTHI 142.5M
- JYNT 170.1M
- IPO Year
- NTHI N/A
- JYNT 2014
- Fundamental
- Price
- NTHI $4.26
- JYNT $11.52
- Analyst Decision
- NTHI
- JYNT Strong Buy
- Analyst Count
- NTHI 0
- JYNT 2
- Target Price
- NTHI N/A
- JYNT $15.50
- AVG Volume (30 Days)
- NTHI 23.3K
- JYNT 65.4K
- Earning Date
- NTHI 01-01-0001
- JYNT 08-07-2025
- Dividend Yield
- NTHI N/A
- JYNT N/A
- EPS Growth
- NTHI N/A
- JYNT N/A
- EPS
- NTHI N/A
- JYNT N/A
- Revenue
- NTHI $79,990.00
- JYNT $52,789,479.00
- Revenue This Year
- NTHI N/A
- JYNT $9.72
- Revenue Next Year
- NTHI N/A
- JYNT $10.92
- P/E Ratio
- NTHI N/A
- JYNT N/A
- Revenue Growth
- NTHI 13.52
- JYNT 71.05
- 52 Week Low
- NTHI $4.11
- JYNT $9.58
- 52 Week High
- NTHI $25.00
- JYNT $15.32
- Technical
- Relative Strength Index (RSI)
- NTHI N/A
- JYNT 53.47
- Support Level
- NTHI N/A
- JYNT $11.48
- Resistance Level
- NTHI N/A
- JYNT $12.49
- Average True Range (ATR)
- NTHI 0.00
- JYNT 0.86
- MACD
- NTHI 0.00
- JYNT -0.04
- Stochastic Oscillator
- NTHI 0.00
- JYNT 42.66
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.